Clinical Study

Mild to moderate Alzheimer's Disease (Oral-2)

The Butler Hospital Memory & Aging Program is conducting a clinical research study of an orally-administered, investigational drug Oral-2 which inhibits the Receptor for Advanced Glycation Endproducts. This study tests whether the investigational drug Oral-2 safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD).

Qualified participants must be:

•  at least 50 years of age
•  diagnosed with mild to moderate Alzheimer's disease
•  not diagnosed with diabetes
•  accompanied by a regular caregiver to 11 study visits over a 1.5-year period

For more information please call 401-455-6403.

All inquiries are confidential.